TherapeuticsMD Inc (TXMD) Earns Outperform Rating from Oppenheimer Holdings, Inc.
TherapeuticsMD Inc (NASDAQ:TXMD)‘s stock had its “outperform” rating reissued by analysts at Oppenheimer Holdings, Inc. in a research note issued on Wednesday. They presently have a $12.00 price target on the stock. Oppenheimer Holdings, Inc.’s price target would indicate a potential upside of 100.33% from the stock’s previous close.
Several other equities analysts have also recently commented on the stock. Cantor Fitzgerald started coverage on shares of TherapeuticsMD in a research note on Friday, December 16th. They set an “overweight” rating for the company. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and set a $10.50 price objective on shares of TherapeuticsMD in a research note on Sunday, December 4th. Guggenheim reaffirmed a “buy” rating on shares of TherapeuticsMD in a research note on Tuesday, November 29th. Stifel Nicolaus boosted their price objective on shares of TherapeuticsMD from $14.00 to $17.00 and gave the company a “buy” rating in a research note on Tuesday, December 6th. Finally, Zacks Investment Research cut shares of TherapeuticsMD from a “hold” rating to a “sell” rating in a research note on Thursday, January 5th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $14.38.
TherapeuticsMD (NASDAQ:TXMD) traded down 0.83% during trading on Wednesday, hitting $5.94. 431,325 shares of the stock traded hands. The company has a 50-day moving average price of $6.14 and a 200-day moving average price of $6.78. TherapeuticsMD has a 12 month low of $4.39 and a 12 month high of $9.29. The stock’s market cap is $1.17 billion.
This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/01/11/therapeuticsmd-inc-txmd-earns-outperform-rating-from-oppenheimer-holdings-inc.html
ILLEGAL ACTIVITY WARNING: “TherapeuticsMD Inc (TXMD) Earns Outperform Rating from Oppenheimer Holdings, Inc.” was posted by American Banking News and is owned by of American Banking News. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2017/01/11/therapeuticsmd-inc-txmd-earns-outperform-rating-from-oppenheimer-holdings-inc.html.
Institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. boosted its position in TherapeuticsMD by 7.1% in the third quarter. BlackRock Inc. now owns 16,303 shares of the company’s stock worth $111,000 after buying an additional 1,080 shares in the last quarter. Traynor Capital Management Inc. boosted its position in TherapeuticsMD by 21.2% in the third quarter. Traynor Capital Management Inc. now owns 20,000 shares of the company’s stock worth $119,000 after buying an additional 3,500 shares in the last quarter. SG Americas Securities LLC bought a new position in TherapeuticsMD during the third quarter worth approximately $137,000. Principal Financial Group Inc. boosted its position in TherapeuticsMD by 1.3% in the third quarter. Principal Financial Group Inc. now owns 20,333 shares of the company’s stock worth $138,000 after buying an additional 261 shares in the last quarter. Finally, DIAM Co. Ltd. bought a new position in TherapeuticsMD during the third quarter worth approximately $139,000.
TherapeuticsMD, Inc is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. It is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. Its drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination.
Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.